Cottu, Paul H <br/><br/>
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.  [electronic resource] 

 -  PloS one  2018 
 - e0204973 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0204973  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--adverse effects<br/>Biomarkers, Tumor--metabolism<br/>Breast Neoplasms--drug therapy<br/>Delayed-Action Preparations<br/>Female<br/>Gonanes--adverse effects<br/>Half-Life<br/>Humans<br/>Middle Aged<br/>Nausea--etiology<br/>Neoplasm Metastasis<br/>Neoplasm Recurrence, Local<br/>Receptors, Progesterone--metabolism